Compare VIOT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | ATRA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 38.9M |
| IPO Year | 2018 | 2014 |
| Metric | VIOT | ATRA |
|---|---|---|
| Price | $1.42 | $6.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 276.0K | 264.1K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $128,940,000.00 |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $3.56 | ★ $2.13 |
| Revenue Growth | N/A | ★ 1404.02 |
| 52 Week Low | $1.18 | $3.92 |
| 52 Week High | $4.33 | $19.15 |
| Indicator | VIOT | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 60.22 |
| Support Level | $1.22 | $4.06 |
| Resistance Level | $1.49 | $13.04 |
| Average True Range (ATR) | 0.08 | 0.76 |
| MACD | 0.01 | 0.39 |
| Stochastic Oscillator | 87.50 | 88.76 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).